BOXED WARNING Fetal toxicity: discontinue as soon as pregnancy is detected; drugs acting on the renin-angiotensin system can cause fetal injury and death.
FDA dosing
Population
Start
Target
Max
Hypertension
Adults & peds ≥6 yr weighing ≥50 kg
150 mg QD
Up to 300 mg QD if not controlled
300 mg QD
Titration Most of the antihypertensive effect (85-90%) is attained by 2 weeks; assess before increasing dose
Renal Safety/effectiveness not established in severe impairment (CrCl <30 mL/min)
Hepatic Undefined
Instructions
Take once daily with a consistent pattern regarding meals; avoid high-fat meals (substantially reduce absorption)
Discontinue as soon as pregnancy is detected
Correct volume and/or salt depletion before starting, or start under close supervision
Contraindications
Concomitant use with ARBs or ACE inhibitors in patients with diabetes
Pediatric patients less than 2 years of age
Cautions
Anaphylactic reactions and head/neck angioedema — discontinue and do not readminister
Pregnancy Can cause fetal harm; RAAS-acting drugs in 2nd/3rd trimesters reduce fetal renal function and increase morbidity/death. Discontinue when pregnancy is detected.
Lactation Breastfeeding not recommended (potential hypotension, hyperkalemia, and renal impairment in the infant).
Defining liabilityGenerally tolerated at therapeutic doses; clinically important risks are agent-specific and increase with interactions or organ impairment.